Montag A & Associates Inc. Sells 2,762 Shares of Stryker Corporation $SYK

Montag A & Associates Inc. lowered its position in Stryker Corporation (NYSE:SYK) by 7.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 33,112 shares of the medical technology company’s stock after selling 2,762 shares during the period. Montag A & Associates Inc.’s holdings in Stryker were worth $10,909,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of SYK. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker during the fourth quarter worth about $26,000. Sankala Group LLC purchased a new position in Stryker in the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker in the 4th quarter worth approximately $27,000. Finally, DJE Kapital AG purchased a new stake in Stryker during the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 1.7%

Shares of SYK opened at $330.26 on Wednesday. The stock has a market capitalization of $126.61 billion, a PE ratio of 38.23, a P/E/G ratio of 2.08 and a beta of 0.77. The company’s fifty day moving average is $309.75 and its 200 day moving average is $338.40. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at $50,170.65. The trade was a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 323,264 shares of company stock valued at $100,659,489 over the last ninety days. 4.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Truist Financial reaffirmed a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Barclays decreased their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Finally, Canaccord Genuity Group cut their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $395.10.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.